Literature DB >> 25171950

Fibroid growth and medical options for treatment.

Nathalie Chabbert-Buffet1, Nathalie Esber2, Philippe Bouchard3.   

Abstract

Although fibroids are common benign tumors, their impact on women's quality of life can be considerable. The most frequent symptoms are uterine bleeding, resulting in anemia, and pelvic pain. Fibroids can be of genetic or hormonal origin or arise from intrauterine events. Current options for medical treatment include control of estradiol and progesterone production or action and are discussed in this review. Although curative treatment of fibroids relies on surgical strategies, the current trend is for uterine-sparing treatment to preserve fertility and avoid unnecessary surgery. Currently approved medical treatments include intrauterine progestin delivery to reduce uterine bleeding, GnRH analogues, and, more recently, selective progesterone receptor modulators to control uterine bleeding and reduce fibroid volume.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibroids; fibroids treatment; progestins; selective estrogen receptor modulators; selective progesterone receptor modulators; sex steroids

Mesh:

Substances:

Year:  2014        PMID: 25171950     DOI: 10.1016/j.fertnstert.2014.07.1238

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  14 in total

1.  Surgical removal of multiple mesenteric fibroids (Kg 4,500) by abdominal spread of previous laparoscopic uterine myomectomy.

Authors:  V Leanza; F A Gulino; G Leanza; G Zarbo
Journal:  G Chir       Date:  2015 Jan-Feb

Review 2.  Adverse bone effects of medications used to treat non-skeletal disorders.

Authors:  N B Watts
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

Review 3.  Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.

Authors:  Molly B Moravek; Serdar E Bulun
Journal:  Curr Opin Obstet Gynecol       Date:  2015-08       Impact factor: 1.927

4.  Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management.

Authors:  Bernice Tsoi; Gord Blackhouse; Simon Ferrazzi; Clare J Reade; Innie Chen; Ron Goeree
Journal:  Clinicoecon Outcomes Res       Date:  2015-04-17

5.  Oestrogen-induced angiogenesis and implantation contribute to the development of parasitic myomas after laparoscopic morcellation.

Authors:  Ben-Shian Huang; Muh-Hwa Yang; Peng-Hui Wang; Hsin-Yang Li; Teh-Ying Chou; Yi-Jen Chen
Journal:  Reprod Biol Endocrinol       Date:  2016-10-06       Impact factor: 5.211

Review 6.  Modern Myoma Treatment in the Last 20 Years: A Review of the Literature.

Authors:  Ahmed El-Balat; Rudy Leon DeWilde; Iryna Schmeil; Morva Tahmasbi-Rad; Sandra Bogdanyova; Ali Fathi; Sven Becker
Journal:  Biomed Res Int       Date:  2018-01-24       Impact factor: 3.411

7.  Blood cadmium and volume of uterine fibroids in premenopausal women.

Authors:  Shinhee Ye; Hye Won Chung; Kyungah Jeong; Yeon-Ah Sung; Hyejin Lee; So Yun Park; Hyunjoo Kim; Eun-Hee Ha
Journal:  Ann Occup Environ Med       Date:  2017-06-22

Review 8.  Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management.

Authors:  Darlene K Taylor; Kristine Holthouser; James H Segars; Phyllis C Leppert
Journal:  F1000Res       Date:  2015-07-06

9.  Is a history of cesarean section a risk factor for abnormal uterine bleeding in patients with uterine leiomyoma?

Authors:  Tugba Kinay; Zehra O Basarir; Serap F Tuncer; Funda Akpinar; Fulya Kayikcioglu; Sevgi Koc; Jale Karakaya
Journal:  Saudi Med J       Date:  2016-08       Impact factor: 1.484

Review 10.  Uterine fibroid management: from the present to the future.

Authors:  Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Hum Reprod Update       Date:  2016-07-27       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.